NVO
REGN
A double-header for the pipeline
Regeneron showed up to the International Gynecologic Cancer Society’s 2026 annual meeting with two very different science projects and, surprisingly, both brought back something worth bragging about. One was ubamatamab, a bispecific antibody aimed at recurrent low-grade serous ovarian cancer. The other was trevogrumab, which Regeneron tested alongside Novo Nordisk’s semaglutide in a muscle-preservation study for people with obesity.
The cancer data is the headline act
The ovarian cancer readout is the kind biotech investors perk up for. In the Phase 1/2 study, patients getting 800 mg monotherapy saw a 73% objective response rate, an 11-month median progression-free survival, and a 9-month median duration of response. That’s not just “nice signal” territory — it’s the sort of result that can move a program from “interesting” to “okay, let’s talk registrational trial.”
Regeneron said it’s enrolling a potentially registrational study and planning to sit down with the FDA about a confirmatory Phase 3. In biotech land, that’s the equivalent of taking your science fair project and asking if it can graduate early.
The obesity angle is more of a side quest, but still relevant
Then there’s trevogrumab. Paired with semaglutide, it was tested to help people keep lean mass while losing weight. The company said lower doses preserved up to 50.7% of lean mass versus semaglutide alone and kept nearly 70% of thigh muscle volume.
That matters because the GLP-1 boom has a tiny awkward problem: people like the weight loss, but not the muscle loss that can tag along. If Regeneron can make that combo work, it could sneak into the next wave of obesity therapy — not as the star, but as the supporting actor investors suddenly care a lot about.
Why you should care
For Regeneron, this is pipeline credibility day. The company is showing:
- a cancer asset with enough traction to justify a bigger study
- a metabolic-program add-on that could matter if GLP-1 combinations become the next battleground
- a partnership-adjacent tie-in with Novo Nordisk, which keeps NVO in the story, but not as the main event
Big picture: biotech stocks live and die by whether the data looks like a starting line or a dead end. This time, Regeneron at least found the starting line — and maybe a lane or two beyond it.